Table 1.
Characteristic | All N=39 |
Not Taking a CYP2D6 Dependent Drug n=12 |
Taking CYP2D6 Dependent Drug n=27 |
---|---|---|---|
Age, median (IQR) | 58 (53, 64) | 60 (58, 65) | 57 (52, 63) |
Male Gender, n (%) | 22 (56%) | 7 (58%) | 15 (56%) |
Race, n (%) Black or African American White |
17 (44%) 22 (56%) |
2 (17%) 10 (83%) |
15 (56%) 12 (44%) |
Hispanic Ethnicity, n (%) Hispanic or Latino |
4 (10%) |
2 (17%) |
2 (7%) |
CYP2D6 Genotype, n (%) Poor Intermediate Normal Ultra rapid |
1 (3%) 5 (13%) 31 (79%) 2 (5%) |
0 (0%) 3 (25%) 9 (75%) 0 (0%) |
1 (4%) 2 (7%) 22 (81%) 2 (7%) |
Number of CYP2D6 Dependent Drugs, including metoprolol succinate 0 1 2 3 |
12 (31%) 16 (41%) 8 (21%) 3 (8%) |
12 (100%) NA NA NA |
NA 16 (59%) 8 (30%) 3 (11%) |
Taking a CYP2D6 inhibitor, n | 4 | NA | 4 |
DM/DX Ratio, median (IQR) | 0.01 (0.01- 0.11) |
0.003 (0.003–0.005) | 0.045 (0.009–0.123) |
MT/MT OH Ratio, median (IQR) |
1.80 (1.12- 4.51) |
NA | 1.80 (1.12–4.51) |